|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM55A |
Gene summary for TMEM55A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM55A | Gene ID | 55529 |
| Gene name | phosphatidylinositol-4,5-bisphosphate 4-phosphatase 2 | |
| Gene Alias | TMEM55A | |
| Cytomap | 8q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8N4L2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55529 | TMEM55A | P91T-E | Human | Esophagus | ESCC | 9.81e-08 | 7.48e-01 | 0.1828 |
| 55529 | TMEM55A | P107T-E | Human | Esophagus | ESCC | 1.86e-02 | 1.16e-01 | 0.171 |
| 55529 | TMEM55A | P126T-E | Human | Esophagus | ESCC | 1.35e-04 | 3.07e-01 | 0.1125 |
| 55529 | TMEM55A | C04 | Human | Oral cavity | OSCC | 5.85e-05 | 4.09e-01 | 0.2633 |
| 55529 | TMEM55A | C21 | Human | Oral cavity | OSCC | 1.02e-16 | 6.27e-01 | 0.2678 |
| 55529 | TMEM55A | C30 | Human | Oral cavity | OSCC | 3.56e-22 | 8.78e-01 | 0.3055 |
| 55529 | TMEM55A | C38 | Human | Oral cavity | OSCC | 1.61e-02 | 3.99e-01 | 0.172 |
| 55529 | TMEM55A | C43 | Human | Oral cavity | OSCC | 3.84e-02 | 2.49e-02 | 0.1704 |
| 55529 | TMEM55A | C46 | Human | Oral cavity | OSCC | 1.55e-06 | 1.66e-01 | 0.1673 |
| 55529 | TMEM55A | C06 | Human | Oral cavity | OSCC | 1.23e-06 | 7.60e-01 | 0.2699 |
| 55529 | TMEM55A | C08 | Human | Oral cavity | OSCC | 3.15e-16 | 3.55e-01 | 0.1919 |
| 55529 | TMEM55A | C09 | Human | Oral cavity | OSCC | 7.34e-04 | 1.18e-01 | 0.1431 |
| 55529 | TMEM55A | LN46 | Human | Oral cavity | OSCC | 4.06e-03 | 2.03e-01 | 0.1666 |
| 55529 | TMEM55A | LP15 | Human | Oral cavity | LP | 2.17e-04 | 4.86e-01 | 0.2174 |
| 55529 | TMEM55A | LP17 | Human | Oral cavity | LP | 4.78e-02 | 4.22e-01 | 0.2349 |
| 55529 | TMEM55A | SYSMH1 | Human | Oral cavity | OSCC | 1.94e-05 | 7.77e-02 | 0.1127 |
| 55529 | TMEM55A | SYSMH2 | Human | Oral cavity | OSCC | 1.95e-06 | 1.52e-01 | 0.2326 |
| 55529 | TMEM55A | SYSMH5 | Human | Oral cavity | OSCC | 6.60e-04 | 1.56e-01 | 0.0647 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM55A | SNV | Missense_Mutation | novel | c.493N>A | p.Glu165Lys | p.E165K | Q8N4L2 | protein_coding | deleterious(0.04) | probably_damaging(0.973) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM55A | SNV | Missense_Mutation | c.677N>A | p.Ser226Tyr | p.S226Y | Q8N4L2 | protein_coding | deleterious(0.02) | possibly_damaging(0.486) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TMEM55A | insertion | Frame_Shift_Ins | novel | c.538dupA | p.Ile180AsnfsTer6 | p.I180Nfs*6 | Q8N4L2 | protein_coding | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
| TMEM55A | deletion | Frame_Shift_Del | novel | c.312delT | p.Leu105SerfsTer10 | p.L105Sfs*10 | Q8N4L2 | protein_coding | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | SD | |||
| TMEM55A | SNV | Missense_Mutation | c.323N>T | p.Lys108Met | p.K108M | Q8N4L2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A6-2685-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TMEM55A | SNV | Missense_Mutation | c.182N>A | p.Cys61Tyr | p.C61Y | Q8N4L2 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TMEM55A | SNV | Missense_Mutation | rs746791765 | c.566N>A | p.Arg189Gln | p.R189Q | Q8N4L2 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TMEM55A | SNV | Missense_Mutation | c.514N>A | p.Ala172Thr | p.A172T | Q8N4L2 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| TMEM55A | SNV | Missense_Mutation | rs746791765 | c.566N>A | p.Arg189Gln | p.R189Q | Q8N4L2 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM55A | SNV | Missense_Mutation | rs758488670 | c.457G>A | p.Val153Met | p.V153M | Q8N4L2 | protein_coding | tolerated(0.08) | possibly_damaging(0.582) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |